Runben Biotechnology Co., Ltd. (SHA:603193)

Runben Biotechnology Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	124.75	185.77	106.59	243.83	368.21	206.19
Short-Term Investments	-	292.94	77.95	1,340	-	-
Trading Asset Securities	1,318	990.17	1,249	19	8.24	56.24
Cash & Short-Term Investments	1,443	1,469	1,434	1,603	376.45	262.43
Cash Growth	27.57%	2.46%	-10.57%	325.85%	43.45%	221.20%
Accounts Receivable	33.48	17.91	13.59	4.82	1.19	2.34
Other Receivables	6.56	4.3	4.62	2.32	6	9.8
Receivables	40.05	22.22	18.22	7.14	7.2	12.15
Inventory	139.46	120.59	118.57	92.91	102.71	56.9
Other Current Assets	25.16	28.33	24.43	13.16	23.68	12.89
Total Current Assets	1,647	1,640	1,595	1,716	510.04	344.36
Property, Plant & Equipment	371.35	295.88	267.57	260.42	277.56	207.67
Other Intangible Assets	86.06	87.32	54.54	18.76	19.36	19.88
Long-Term Deferred Tax Assets	56.33	50.43	44.23	20.82	14.8	5.66
Long-Term Deferred Charges	1.92	1.51	1.26	1.41	-	-
Other Long-Term Assets	259.94	262.61	256.9	1.13	3.65	68.77
Total Assets	2,423	2,338	2,219	2,019	825.42	646.34

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	71.27	-	-	40.15	36.99	46.37
Accrued Expenses	10.12	36.27	32.16	26.21	24.43	11.41
Current Portion of Leases	0.36	1.42	1.37	1.95	2.51	2.4
Current Income Taxes Payable	23.27	4.44	26.29	15.47	18.28	5.29
Current Unearned Revenue	3.95	11.38	13.37	5.97	4.5	4.2
Other Current Liabilities	7.88	59.37	64.01	5.36	9.89	5.84
Total Current Liabilities	116.84	112.88	137.19	95.12	96.6	75.52
Long-Term Leases	-	-	1.42	2.04	5.39	7.91
Long-Term Unearned Revenue	3.29	3.78	0.01	0.01	0.27	1.13
Long-Term Deferred Tax Liabilities	0.16	0.13	0.27	0.44	0.57	0.14
Total Liabilities	120.29	116.79	138.88	97.61	102.83	84.69

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	404.59	404.59	404.59	404.59	343.9	343.9
Additional Paid-In Capital	1,015	1,015	1,015	1,015	102.59	101.69
Retained Earnings	882.81	801.2	660.67	502.12	276.09	116.05
Shareholders' Equity	2,303	2,221	2,080	1,921	722.59	561.65
Total Liabilities & Equity	2,423	2,338	2,219	2,019	825.42	646.34

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	0.36	1.42	2.78	4	7.91	10.31
Net Cash (Debt)	1,442	1,467	1,431	1,599	368.54	252.12
Net Cash Growth	27.73%	2.56%	-10.52%	333.90%	46.18%	208.59%
Net Cash Per Share	3.56	3.64	3.53	4.53	1.08	0.75
Filing Date Shares Outstanding	404.59	404.59	404.59	404.59	404.59	343.9
Total Common Shares Outstanding	404.59	404.59	404.59	404.59	343.9	343.9
Working Capital	1,530	1,527	1,458	1,621	413.44	268.84
Book Value Per Share	5.69	5.49	5.14	4.75	2.10	1.63
Tangible Book Value	2,217	2,134	2,026	1,903	703.22	541.76
Tangible Book Value Per Share	5.48	5.27	5.01	4.70	2.04	1.58
Buildings	-	231.94	231.94	232.54	231.65	163.47
Machinery	-	105.34	96.7	87.77	79.06	57.22
Construction In Progress	-	58.15	18.07	1.82	5.76	7.17

Data Source: S&P Global Market Intelligence Last updated: Oct 19, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 26, 2026

Data Sources Report a data error